Hemenway Trust Co LLC trimmed its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 13.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,205 shares of the medical instruments supplier's stock after selling 8,224 shares during the quarter. Hemenway Trust Co LLC's holdings in Becton, Dickinson and Company were worth $11,617,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in BDX. Wesbanco Bank Inc. raised its position in shares of Becton, Dickinson and Company by 1.9% in the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier's stock worth $580,000 after acquiring an additional 48 shares during the period. S.A. Mason LLC increased its holdings in shares of Becton, Dickinson and Company by 3.7% during the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier's stock worth $321,000 after buying an additional 50 shares during the last quarter. Hillsdale Investment Management Inc. lifted its position in Becton, Dickinson and Company by 1.7% in the fourth quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier's stock valued at $694,000 after buying an additional 50 shares during the last quarter. Americana Partners LLC raised its holdings in shares of Becton, Dickinson and Company by 3.5% in the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier's stock valued at $345,000 after buying an additional 52 shares during the period. Finally, Picton Mahoney Asset Management boosted its position in Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after buying an additional 54 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of the stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president now owns 4,887 shares in the company, valued at approximately $964,107.36. This represents a 8.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bertram L. Scott sold 700 shares of the business's stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the completion of the transaction, the director now directly owns 36,033 shares of the company's stock, valued at approximately $8,215,163.67. This trade represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 4,675 shares of company stock valued at $1,057,182 in the last 90 days. 0.36% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on BDX shares. Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 28th. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating for the company in a research report on Monday. Finally, StockNews.com raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, April 2nd. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of "Buy" and an average target price of $275.71.
Get Our Latest Research Report on Becton, Dickinson and Company
Becton, Dickinson and Company Stock Performance
Becton, Dickinson and Company stock traded down $9.72 during midday trading on Thursday, hitting $199.63. 1,363,595 shares of the company's stock were exchanged, compared to its average volume of 1,672,952. The firm's 50 day simple moving average is $225.75 and its 200 day simple moving average is $230.36. Becton, Dickinson and Company has a 12-month low of $193.03 and a 12-month high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The stock has a market cap of $57.32 billion, a price-to-earnings ratio of 33.00, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.
Becton, Dickinson and Company Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.08%. The ex-dividend date was Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is currently 69.10%.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
